Raafat Iskander, MD
Neurology · Los Angeles, CANPI 1407958234
Payments from drug & device makers
Across 603 payments — averaging $28.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$3K
- Supernus Pharmaceuticals, Inc.$2K
- Biogen$2K
- Sunovion Pharmaceuticals Inc.$1K
- Aquestive Therapeutics, Inc.$1K
- Eisai Inc.$1K
- plus $8K from 32 others
What the payments were for
- Speaking & faculty fees$5003%
- Food & beverage$16,59997%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 77 | $2,534 |
| Supernus Pharmaceuticals, Inc. | 76 | $1,694 |
| Biogen | 71 | $1,588 |
| Sunovion Pharmaceuticals Inc. | 75 | $1,440 |
| Aquestive Therapeutics, Inc. | 34 | $1,079 |
| Eisai Inc. | 24 | $1,016 |
| Greenwich Biosciences, Inc. | 34 | $1,010 |
| SK Life Science, Inc. | 20 | $947 |
| Neurelis, Inc. | 27 | $944 |
| Sumitomo Pharma America, Inc. | 45 | $930 |
| Amneal Pharmaceuticals LLC | 34 | $753 |
| Harmony Biosciences LLC | 14 | $723 |
| Livanova USA, Inc. | 10 | $425 |
| Catalyst Pharmaceuticals, Inc. | 9 | $369 |
| Novartis | 7 | $255 |
| Jazz Pharmaceuticals Inc. | 5 | $153 |
| Boston Scientific | 4 | $144 |
| EMD Serono, Inc. | 1 | $121 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| Immedica Pharma US, Inc. | 3 | $91 |
| Zogenix Inc. | 4 | $88 |
| MDD US Operations, LLC | 4 | $87 |
| Lundbeck LLC | 3 | $78 |
| Argenx US, Inc. | 3 | $71 |
| AstraZeneca | 2 | $61 |
| Acadia Pharmaceuticals Inc | 2 | $60 |
| Idorsia Pharmaceuticals US Inc | 1 | $48 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Lilly USA, LLC | 1 | $35 |
| Upsher-smith Laboratories LLC | 1 | $33 |
| Cycle Pharmaceuticals Inc | 1 | $33 |
| Sanofi | 1 | $32 |
| CSL Behring | 1 | $32 |
| Tanabe Pharma America, Inc. | 1 | $27 |
| Bristol Myers Squibb | 1 | $26 |
| Aucta Pharmaceuticals, Inc. | 1 | $19 |
| Cranial Technologies, Inc | 1 | $16 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,124 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 14 | $307,180 |
| AptiomEslicarbazepine Acetate | 91 | $140,436 |
| FycompaPerampanel | 62 | $60,313 |
| AustedoDeutetrabenazine | 13 | $31,179 |
| Lamotrigine OdtLamotrigine | 60 | $20,154 |
| Clobazam | 146 | $19,382 |
| RytaryCarbidopa/Levodopa | 26 | $15,484 |
| Aripiprazole OdtAripiprazole | 13 | $12,456 |
| EliquisApixaban | 18 | $11,691 |
| Topiramate ErTopiramate | 20 | $8,705 |
| Lacosamide | 155 | $7,349 |
| Levetiracetam | 153 | $3,488 |
| Propranolol Hcl ErPropranolol Hcl | 130 | $1,685 |
| Memantine Hcl | 136 | $1,642 |
| Divalproex Sodium | 63 | $1,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Aptiom | $1,440 | $140,43691 claims |
| Eisai Inc.Fycompa | $1,016 | $60,31362 claims |
| Amneal Pharmaceuticals LLCRytary | $753 | $15,48426 claims |
| Upsher-smith Laboratories LLCTopiramate | $33 | $853100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.
Other neurology in Los Angeles
- Timothy CloughesyLos Angeles$33.1M
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.